Key result
Registry initiatives boost underused post-MI secondary prevention therapies across Europe.
Why the study?
The use of evidence-based secondary prevention treatments after myocardial infarction varies across Europe and is generally under-utilised.
Population
Patients with acute myocardial infarction or chronic heart failure in Europe
Comparison
Use versus under-utilisation of secondary prevention treatments including beta blockers and ACE inhibitors
Design
Review of surveys and registry data
Authors
Discussion
Loading...
Member takes
Overview
HF/LVSD identification post-MI aids risk stratification; leaves open optimal guideline implementation in contemporary practice.
Structured PICO
P
Population
Patients with acute myocardial infarction or chronic heart failure
E
Exposure
Secondary prevention treatments (including beta blockers and angiotensin converting enzyme inhibitors)
Evidence-based secondary prevention therapies are under-utilized in Europe, but targeted registries and collaborations can improve guideline adherence.
Cite This Study
Karl B Swedberg (2005) conducted a review in acute myocardial infarction and chronic heart failure. Secondary prevention treatments was evaluated. Secondary prevention therapies for myocardial infarction are under-utilized in Europe, but initiatives like the Italian BRING-UP and Swedish RIKS-HIA registries have successfully increased their use.